Company: CERO
Filing Date: 2025-11-20
Form Type: 424B3
Source: 0001213900-25-113117
Chunk: 15

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-11-20
Form: 424B3
Chunk 15
---
500,000 |   |     | $            |         - |   |
| Issuance of common shares to Arena Investors LP for equity line of credit                                        |     | $             |           - |   |     | $             |     500,000 |   |     | $            |         - |   |
| Conversion of Series A, Series B, Series C and Series D Preferred Stock to common stock                          |     | $             |   2,271,098 |   |     | $             |           - |   |     | $            |         - |   |
| Reclassification of deferred offering costs to additional paid-in capital                                        |     | $             |     112,232 |   |     | $             |           - |   |     | $            |         - |   |
| Reclassification of accrued expenses to accounts payable                                                         |     | $             |   1,143,826 |   |     | $             |           - |   |     | $            |         - |   |
| Issuance of Series D Preferred Stock for investment in equity securities                                         |     | $             |     500,000 |   |     | $             |           - |   |     | $            |         - |   |
| Write off of subscription receivable deemed offering cost                                                        |     | $             |      78,750 |   |     | $             |           - |   |     | $            |         - |   |

<div align='center'>See accompanying notes to the condensed consolidated
financial statements

5

CERO THERAPEUTICS HOLDINGS, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
September 30, 2025

(Unaudited)</div>

NOTE 1 – ORGANIZATION AND DESCRIPTION OF THE BUSINESS

Nature of Operations –
CERo Therapeutics Holdings, Inc. (OTC PINK: CERO) (“CERo”, “Successor” or the “Company”), F/K/A Phoenix
Biotech Acquisition Corp. (“PBAX”) was incorporated in Delaware on June 8, 2021. PBAX was formed for the purpose of effecting
a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more
businesses (a “business combination”).

The Company is an innovative
immunotherapy company advancing the development of next generation engineered T